20485-38-5

Upstream product

• 2298-36-4 4-aminophenoxyacetic acid 
• 123-30-8 4-amino-phenol 
• 105-39-5 chloroacetic acid ethyl ester 
• 105-36-2 ethyl bromoacetate 
• 19076-89-2 ethyl 4-nitrophenoxyacetate 
• 100-02-7 4-nitro-phenol 
• 19786-48-2 methyl 2-(4-nitrophenoxy)acetate 

Downstream Products

• 6327-96-4 (4-N,N-bis(2-hydroxyethyl)phenoxy)acetic acid ethyl ester 
• 72131-55-6 ethyl 2-{4-[(phenylsulfonyl)amino]phenoxy}acetate 
• 126684-65-9 etile 4-(3-oxo-1,2-benzisotiazolin-2-il)fenossiacetato 
• 103790-28-9 [4-(2-Nitro-benzenesulfonylamino)-phenoxy]-acetic acid ethyl ester 
• 103790-29-0 [4-(4-Bromo-benzenesulfonylamino)-phenoxy]-acetic acid ethyl ester 
• 195885-23-5 {4-[3-(5-Methoxy-2-methoxymethoxy-phenyl)-ureido]-phenoxy}-acetic acid ethyl ester 
• 198627-49-5 ethyl 4-(2,2-diethoxyethylamino)phenoxyacetate 
• 106077-12-7 Ethyl-<4-(4-oxo-2-phenyl-3(4H)-quinazolinyl)phenoxy>acetate 
• 1078736-58-9 (R)-{4-[{2-[3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl}amino]phenoxy}acetic acid ethyl ester 
• 1161863-81-5 C₂₀H₁₈N₂O₄ 
• 1310744-78-5 (R)-dimethyl 2-(3-(((4-(2-ethoxy-2-oxoethoxy)phenyl)amino)methyl)benzamido)pentanedioate 
• 1310744-79-6 (R)-2-(3-(((4-(carboxymethoxy)phenyl)amino)methyl)benzamido)pentanedioic acid 
• 1616380-27-8 2-(4-((4-((3-acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)acetic acid 
• 1616380-90-5 ethyl 2-(4-((4-((3-acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)acetate 

Relevant academic research and scientific papers

Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARγ agonist) for the treatment of experimental type 2 diabetes

The current manuscript describes two molecules that were designed against PPARγ and GPR40 receptors. The preparation of the compounds was carried out following a synthetic route of multiple steps. Then, the mRNA expression levels of PPARγ, GLUT4, and GPR4

Pyrazolo[3,4-c]pyridine derivative

The invention relates to a pyrazolo[3,4-c]pyridine derivative. The invention relates to a compound represented by a formula (I), a tautomer thereof, an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein the formula (I) is shown in the description, and Z, X, RNc, RNd, RNe and RNf are defined according to the claim 1. The invention further relates to the pharmaceutical composition contain the compound. The invention further relates to use of the compound or the pharmaceutical composition in preparing a drug for preventing and/or treating a disease which inhibits positive influence of an Xa factor, particularly use in preparing the drug for preventing and/or treating the disease which inhibits positive influence of the Xa factor under the condition of low hemorrhage risk.

GK and PPAR dual agonist activity aryl urea derivatives

The invention discloses a novel arylurea derivative, its preparation method, pharmaceutical composition and application. Specifically, the invention relates to an arylurea derivative as shown in the general formula I, its medicinal salt, a preparation met

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

CONJUGATES AND SMALL MOLECULES WHICH INTERACT WITH THE CD16A RECEPTOR

The invention is related to medicine, in particular, to oncology and immunology. The novel compounds of the general formula 1 or 2, exhibiting affinity for CD16a receptor have been proposed. There were also proposed novel modified proteins active towards

AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect

Compound {4-[({4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy}acetyl)amino]phenoxy}acetic acid (1) was prepared and the in vitro relative expression of PPARγ, GLUT-4 and PPARα, was estimated. Compound 1 showed an increase of 2-fold in the mRNA

HETEROCYCLIC UREA COMPOUNDS

The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture